The algorithm can also reduce imaging time and improve the patient experience.

PET using a new voltage-sensitive tracer displayed promise for analyzing activity inside the mitochondria of lung cancer tumors, information that may be valuable for predicting a patient's response to treatment.

A team of Swedish researchers found that a hybrid planar and SPECT imaging method fell short in accurately measuring the absorbed treatment dose in some patients, but importantly, performed well in those with bone marrow metastases.

Canadian Nuclear Laboratories and TRIUMF, the country’s particle accelerator center, have successfully produced actinium-225—a rare isotope that can be used for novel cancer therapy treatments.

Exposure to radioiodine can lead to DNA damage in thyroid cells and other tissue, but new research suggests current radiation protection principles may not be sufficiently monitoring radiation exposure to nuclear medicine professionals.

Pairing multispectral optoacoustic tomography with ultrasound provided biomarker information that may better diagnose patient's with autoimmune diseases and thyroid nodules.

Results from a study published Oct. 14 in Nature Communications showed the tracer could identify pancreatic, cervical and lung cancer, in addition to a lung tissue disease called idiopathic pulmonary fibrosis.

“At the end of five years, we hope to have a radioactive tracer that will be able to detect Parkinson’s early on and provide detailed information about the disease’s progression, which is critical for discovering and testing new treatments," said Robert H. Mach, PhD, a researcher involved in the project.

The funds, managed by Oaktree Capital Management, will support SHINE’s commercialization of molybdenum-99 and lutetium-177 (Lu-177) in addition to construction of the physical production facility.

Standardizing protocols for preclinical PET/CT imaging can help translate research findings to the clinical setting, according to a study published Sept. 27 in the Journal of Nuclear Medicine.

Metrics based on PET/CT imaging can identify neuroendocrine tumor patients who may benefit from peptide receptor radionuclide therapy (PRRT) better than traditional imaging-based scoring measures, according to a study published in the September issue of The Journal of Nuclear Medicine.

Authors of a new study published Sept. 20 in the Journal of Nuclear Medicine argue that gallium-68 (68Ga) prostate-specific membrane antigen (PSMA)-11 PET/CT imaging can offer additional insight into bone metastases in prostate cancer patients and should be more widely used.